M&A / Deals Otsuka grows in neuroplastogens with $1.225bn Transcend buy PharmaphorumOtsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.M&A / DealsNeuroscienceRead full story pharminent March 29, 2026 (Last updated: March 30, 2026) Pharmaphorum Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials. M&A / DealsNeuroscienceRead full story Post navigation Previous: Lilly puts up to $2.75bn into Insilico allianceNext: Trustworthy AI in clinical oversight Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
